
Elmood45 mg+105
Eskayef Bangladesh Ltd.
Dextromethorphan + Bupropion is an oral combination product containing dextromethorphan (an NMDA receptor antagonist and sigma-1 receptor agonist) and bupropion (which here also acts as a CYP2D6…
Dextromethorphan + Bupropion is an oral combination product containing dextromethorphan (an NMDA receptor antagonist and sigma-1 receptor agonist) and bupropion (which here also acts as a CYP2D6 inhibitor to raise dextromethorphan exposure). It represents a non-monoaminergic mechanism distinct from traditional antidepressants.
Dextromethorphan + Bupropion has not been shown to be effective, and is not indicated, for anxiety disorders, cough suppression, or any use in patients under 18 years of age. It should be prescribed only for its approved indications, under medical supervision.
Dosing of Dextromethorphan + Bupropion differs by indication and is titrated over the first 1-2 weeks of treatment.
| Indication/Population | Dose | Notes |
|---|---|---|
| Adults - Major depressive disorder | One tablet (45 mg/105 mg) once daily (morning) for the first 3 days, then increase to one tablet twice daily, at least 8 hours apart, from day 4 onward | Maximum 2 tablets (90 mg/210 mg) per 24 hours |
| Adults - Agitation associated with Alzheimer's disease dementia | Lower starting dose once daily for the first week, increased to twice daily (at least 8 hours apart) in the second week, with further increase to the standard twice-daily dose from around day 15 based on response and tolerability | Titration schedule and target dose are determined by the prescriber; not for as-needed use |
| Moderate renal impairment | Reduced to once-daily dosing | Severe renal impairment/end-stage renal disease: not recommended (not adequately studied) |
| Known CYP2D6 poor metabolizers or concurrent strong CYP2D6 inhibitor use | Reduced to once-daily dosing | Higher dextromethorphan exposure expected; see Interactions |
| Moderate-to-severe hepatic impairment | Not recommended | Bupropion exposure is significantly increased |
| Children/adolescents | Not approved | Safety and efficacy not established (see Pediatric Uses) |
Tablets of Dextromethorphan + Bupropion should be swallowed whole with water and must not be crushed, split, or chewed, as this could increase the rate of drug release. It may be taken with or without food; avoid dosing close to bedtime because of the risk of insomnia.
Side effects of Dextromethorphan + Bupropion reported in clinical studies include:
Patients should seek prompt medical attention for a seizure, chest pain, signs of an allergic reaction, confusion, hallucinations, or thoughts of self-harm.
See Precautions and Warnings for cautions and risk factors that do not amount to absolute contraindications.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.